Paradigm Biocapital Advisors’s Maze Therapeutics MAZE Stock Holding History

Paradigm Biocapital Advisors’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$81.9M	Buy	+2,744,399	New	+$121M	1.67%	20

Other funds holding MAZE

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Paradigm Biocapital Advisors's MAZE Position: Q1 2026 in Review

Paradigm Biocapital Advisors opened a new position in Maze Therapeutics (MAZE) in Q1 2026: 2,744,399 shares worth $81.9M. The stake represents 1.67% of the portfolio and ranks #20 among its holdings.

165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

Paradigm Biocapital Advisors held 2,744,399 shares of Maze Therapeutics worth $81.9M as of Q1 2026.
Maze Therapeutics was a new Paradigm Biocapital Advisors position in Q1 2026.
Maze Therapeutics made up 1.67% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #20 holding.
165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.